MESP1

Summary

MESP1 (mesoderm posterior bHLH transcription factor 1, HGNC:29658) is a protein-coding gene on chromosome 15q26.1, encoding Mesoderm posterior protein 1 (Q9BRJ9). Transcription factor.

Enables DNA-binding transcription factor activity and transcription cis-regulatory region binding activity. Involved in several processes, including endothelial cell differentiation; heart development; and positive regulation of transcription by RNA polymerase II. Predicted to be located in chromatin. Predicted to be active in nucleus. Implicated in myocardial infarction. Biomarker of diabetic retinopathy.

Source: NCBI Gene 55897 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Moderate, ClinGen)
• GWAS associations: 1
• Clinical variants (ClinVar): 70 total
• MANE Select transcript: NM_018670

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29658
Approved symbol	MESP1
Name	mesoderm posterior bHLH transcription factor 1
Location	15q26.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC10676, bHLHc5
Ensembl gene	ENSG00000166823
Ensembl biotype	protein_coding
OMIM	608689
Entrez	55897

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000300057, ENST00000559894

RefSeq mRNA: 1 — MANE Select: NM_018670 NM_018670

CCDS: CCDS10355

Canonical transcript exons

ENST00000300057 — 2 exons

Exon	Start	End
ENSE00001106967	89749875	89750227
ENSE00001183307	89750509	89751249

Expression profiles

Bgee: expression breadth ubiquitous, 187 present calls, max score 89.14.

FANTOM5 (CAGE): breadth broad, TPM avg 1.7350 / max 72.3035, expressed in 593 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151479	0.7726	342
151480	0.5429	271
151481	0.2000	45
151478	0.1960	80
151482	0.0235	11

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	89.14	gold quality
oocyte	CL:0000023	86.81	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.46	gold quality
nasal cavity epithelium	UBERON:0005384	86.08	silver quality
secondary oocyte	CL:0000655	85.79	gold quality
prefrontal cortex	UBERON:0000451	85.61	gold quality
amygdala	UBERON:0001876	83.99	gold quality
anterior cingulate cortex	UBERON:0009835	83.62	gold quality
hindlimb stylopod muscle	UBERON:0004252	83.23	gold quality
gastrocnemius	UBERON:0001388	82.70	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.46	gold quality
frontal cortex	UBERON:0001870	82.35	gold quality
neocortex	UBERON:0001950	81.99	gold quality
middle temporal gyrus	UBERON:0002771	81.99	gold quality
right frontal lobe	UBERON:0002810	81.95	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.79	gold quality
prostate gland	UBERON:0002367	81.45	gold quality
temporal lobe	UBERON:0001871	81.32	gold quality
hypothalamus	UBERON:0001898	81.28	gold quality
kidney epithelium	UBERON:0004819	81.27	gold quality
muscle of leg	UBERON:0001383	80.95	gold quality
cerebral cortex	UBERON:0000956	80.89	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	80.71	silver quality
heart right ventricle	UBERON:0002080	80.42	gold quality
adipose tissue	UBERON:0001013	80.34	gold quality
skeletal muscle tissue	UBERON:0001134	79.99	gold quality
Ammon’s horn	UBERON:0001954	79.95	gold quality
cerebellar vermis	UBERON:0004720	79.66	silver quality
telencephalon	UBERON:0001893	79.24	gold quality
nucleus accumbens	UBERON:0001882	79.10	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	203.95
E-ANND-3	no	2.48

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
DKK1	Activation

Upstream regulators (CollecTRI, top): CTNNB1, LEF1, POU5F1

miRNA regulators (miRDB)

10 targeting MESP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-4712-5P	97.24	67.79	775
HSA-MIR-770-5P	97.24	68.10	758
HSA-MIR-346	97.01	66.97	662

Literature-anchored findings (GeneRIF, showing 10)

• MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling (PMID:18297060)
• Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors. (PMID:22826236)
• MESP1 SNPs are associated with congenital heart disease in patients and altered transcription in vitro. (PMID:24056064)
• The MESP1-NKX2-5 hESC reporter line allows us to identify molecular cues crucial for specification and expansion of human cardiac mesoderm and early progenitors and their differentiation to specific cardiovascular derivatives. (PMID:25187301)
• results suggest that pathologic variants in MESP1 may contribute to the development of congenital heart disease (CHD) and that additional protein partners and downstream targets could likewise contribute to the wide range of causes for CHD (PMID:26694203)
• The present study firstly provided experimental evidence supporting the concept that a MESP1 lossoffunction mutation may contribute to the development of double outlet right ventricle in humans, which presents a significant insight into the molecular pathogenesis of congenital heart disease. (PMID:28677747)
• Study demonstrates that while leaving primitive streak markers unaffected, MESP1 expression is required for timely vascular progenitor specification. Thus, MESP1 expression is essential for the molecular features of early CM, EC and VSMC lineage specification. (PMID:30389344)
• we demonstrate that upregulation of MESP1, a key tumor-promoting alteration, functions to create tumor dependency on an inbuilt lineage-survival process. MESP1, being the nodal point of this survival process, sustains the tumor dependency by transcriptionally activating key genes involved in tumor cell initiation, proliferation and progression including EMT (PMID:31761621)
• Essential role of MESP1-RING1A complex in cardiac differentiation. (PMID:36413948)
• MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. (PMID:37271034)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	mespaa	ENSDARG00000017078
danio_rerio	mespba	ENSDARG00000030347
danio_rerio	mespab	ENSDARG00000068761
danio_rerio	mespbb	ENSDARG00000097947
mus_musculus	Mesp1	ENSMUSG00000030544
rattus_norvegicus	Mesp1	ENSRNOG00000014951
drosophila_melanogaster	sage	FBGN0037672

Paralogs (2): MSGN1 (ENSG00000151379), MESP2 (ENSG00000188095)

Protein

Protein identifiers

Mesoderm posterior protein 1 — Q9BRJ9 (reviewed: Q9BRJ9)

Alternative names: Class C basic helix-loop-helix protein 5

All UniProt accessions (1): Q9BRJ9

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor. Plays a role in the epithelialization of somitic mesoderm and in the development of cardiac mesoderm. Defines the rostrocaudal patterning of the somites by participating in distinct Notch pathways.

Subcellular location. Nucleus.

Miscellaneous. The N- and C-terminal domains are separated by a 2-repeat G-Q region.

RefSeq proteins (1): NP_061140* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011598	bHLH_dom	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR040259	Mesogenin/MesP	Family

Pfam: PF00010

UniProt features (11 total): repeat 2, region of interest 2, compositionally biased region 2, chain 1, domain 1, sequence conflict 1, short sequence motif 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRJ9-F1	62.31	0.20

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9733709	Cardiogenesis
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 196 (showing top): GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GCACCTT_MIR18A_MIR18B, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_CELL_MIGRATION_INVOLVED_IN_HEART_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, GOBP_AXIS_SPECIFICATION, GOBP_CORONARY_VASCULATURE_DEVELOPMENT, GOBP_CARDIAC_CHAMBER_MORPHOGENESIS, GOBP_EMBRYONIC_AXIS_SPECIFICATION, GOBP_FORMATION_OF_PRIMARY_GERM_LAYER

GO Biological Process (36): mesoderm formation (GO:0001707), heart looping (GO:0001947), heart morphogenesis (GO:0003007), heart induction (GO:0003129), secondary heart field specification (GO:0003139), embryonic heart tube morphogenesis (GO:0003143), cardiac atrium formation (GO:0003210), cardiac ventricle formation (GO:0003211), sinus venosus morphogenesis (GO:0003236), growth involved in heart morphogenesis (GO:0003241), cardioblast anterior-lateral migration (GO:0003259), regulation of transcription by RNA polymerase II (GO:0006357), Notch signaling pathway (GO:0007219), gastrulation (GO:0007369), mesodermal cell migration (GO:0008078), gene expression (GO:0010467), neurogenesis (GO:0022008), signal transduction involved in regulation of gene expression (GO:0023019), somite rostral/caudal axis specification (GO:0032525), negative regulation of mesodermal cell fate specification (GO:0042662), negative regulation of endodermal cell fate specification (GO:0042664), endothelial cell differentiation (GO:0045446), positive regulation of Notch signaling pathway (GO:0045747), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), lateral mesoderm development (GO:0048368), positive regulation of striated muscle cell differentiation (GO:0051155), cardiac muscle cell differentiation (GO:0055007), cardiac cell fate determination (GO:0060913), sinoatrial node cell differentiation (GO:0060921), cardiac vascular smooth muscle cell differentiation (GO:0060947), cardioblast migration to the midline involved in heart field formation (GO:0060975), positive regulation of hepatocyte differentiation (GO:0070368), negative regulation of canonical Wnt signaling pathway (GO:0090090), cardioblast migration (GO:0003260)

GO Molecular Function (10): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA-binding transcription factor activity (GO:0003700), protein dimerization activity (GO:0046983), cis-regulatory region sequence-specific DNA binding (GO:0000987), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
heart field specification	2
heart morphogenesis	2
embryonic morphogenesis	2
cardiac chamber formation	2
regulation of DNA-templated transcription	2
transcription cis-regulatory region binding	2
formation of primary germ layer	1
mesoderm morphogenesis	1
embryonic heart tube morphogenesis	1
determination of heart left/right asymmetry	1
heart development	1
animal organ morphogenesis	1
organ induction	1
regulation of heart morphogenesis	1
embryonic heart tube development	1
embryonic organ morphogenesis	1
epithelial tube morphogenesis	1
cardiac atrium morphogenesis	1
cardiac ventricle morphogenesis	1
cardiac chamber morphogenesis	1
sinus venosus development	1
heart growth	1
developmental growth involved in morphogenesis	1
cardioblast migration	1
transcription by RNA polymerase II	1
cell surface receptor signaling pathway	1
ectoderm formation	1
endoderm formation	1
mesoderm formation	1
ameboidal-type cell migration	1
macromolecule biosynthetic process	1
nervous system development	1
cell differentiation	1
signal transduction	1
regulation of gene expression	1
embryonic axis specification	1
somitogenesis	1
anterior/posterior axis specification	1
mesodermal cell fate specification	1

Protein interactions and networks

STRING

498 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MESP1	SOX17	Q9H6I2	802
MESP1	NKX2-5	P52952	779
MESP1	GATA4	P43694	748
MESP1	MEF2C	Q06413	709
MESP1	HAND2	P61296	701
MESP1	FOXC2	Q99958	667
MESP1	FOXC1	Q12948	630
MESP1	TBX5	Q99593	629
MESP1	MIXL1	Q9H2W2	614
MESP1	DLL1	O00548	597
MESP1	FOXA2	Q9Y261	595
MESP1	LFNG	Q8NES3	589
MESP1	EFNB2	P52799	564
MESP1	FOXQ1	Q9C009	560
MESP1	ISL1	P20663	556

IntAct

5 interactions, top by confidence:

A	B	Type	Score
MESP1	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
TCF3	MESP1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (12): RING1 (Two-hybrid), TCF3 (Two-hybrid), ZIC3 (Two-hybrid), RING1 (Affinity Capture-Western), TCF3 (Affinity Capture-Western), MESP1 (Co-localization), EP300 (Affinity Capture-Western), PHC1 (Affinity Capture-Western), SMC1A (Affinity Capture-Western), SMC3 (Affinity Capture-Western), RAD21 (Affinity Capture-Western), CTCF (Affinity Capture-Western)

ESM2 similar proteins: A0A8I5KY20, A4IHR5, A6H7J1, A7UKY7, B7Z1M9, C9JLR9, E1BDF2, F5GYI3, G3V9M2, P0CG09, P0CG25, Q01101, Q0IIA6, Q0PHV7, Q13387, Q2TAM9, Q32KV8, Q4VA45, Q52KG4, Q5U4P2, Q63ZV0, Q673H1, Q69YZ2, Q6P6N5, Q6PAJ3, Q6PJ61, Q7L591, Q7Z6J2, Q86SH2, Q86UD0, Q8BNN1, Q8IUW3, Q8IYG6, Q8N554, Q8NBR0, Q8R4T5, Q8TF61, Q96C00, Q96G42, Q96IQ9

Diamond homologs: A6NI15, O08574, O09105, O42202, P41894, P46581, P48986, P79765, P79766, P79920, P97309, Q08DI0, Q0VG99, Q13562, Q28C89, Q4R5G6, Q60430, Q60867, Q64289, Q90ZL1, Q91616, Q96NK8, Q9BRJ9, Q9DEQ9, Q9HD90, Q9JK54, Q9W690, Q9W6C7, Q9Y4Z2, A8E5T6, O35437, O43680, O60682, O88940, P79782, Q10574, Q20561, Q32PV5, Q5E9S3, Q6GNB7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

141 predictions. Top by Δscore:

Variant	Effect	Δscore
15:89750798:T:A	donor_gain	0.9800
15:89750692:AG:A	donor_gain	0.9700
15:89750764:G:GC	donor_gain	0.9300
15:89750700:T:TA	donor_gain	0.9100
15:89750228:C:CC	acceptor_gain	0.8700
15:89750225:GAGC:G	acceptor_loss	0.8600
15:89750226:AGCTG:A	acceptor_loss	0.8600
15:89750227:GCTGT:G	acceptor_loss	0.8600
15:89750228:C:A	acceptor_loss	0.8600
15:89750229:T:A	acceptor_loss	0.8600
15:89750763:CG:C	donor_gain	0.8400
15:89750224:GGAG:G	acceptor_gain	0.8300
15:89750225:GAG:G	acceptor_gain	0.7800
15:89750223:AGGAG:A	acceptor_gain	0.7600
15:89750760:CCGCG:C	donor_gain	0.7600
15:89750693:G:GA	donor_gain	0.7400
15:89750769:C:CT	donor_gain	0.7300
15:89750226:AG:A	acceptor_gain	0.7200
15:89750768:CCGCG:C	donor_gain	0.7200
15:89750693:G:C	donor_gain	0.7100
15:89750765:TC:T	donor_gain	0.7100
15:89750770:G:T	donor_gain	0.6700
15:89750230:G:C	acceptor_gain	0.6600
15:89750766:C:T	donor_gain	0.6500
15:89750701:C:A	donor_gain	0.6300
15:89750761:CGCG:C	donor_gain	0.5900
15:89750357:G:A	donor_gain	0.5700
15:89750352:T:A	donor_gain	0.5600
15:89750353:C:A	donor_gain	0.5500
15:89750500:GACAC:G	donor_loss	0.5500

AlphaMissense

1682 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:89750866:C:A	K122N	0.997
15:89750866:C:G	K122N	0.997
15:89750870:G:A	T121I	0.996
15:89750960:T:A	E91V	0.996
15:89750947:C:A	M95I	0.995
15:89750947:C:G	M95I	0.995
15:89750947:C:T	M95I	0.995
15:89750959:C:A	E91D	0.995
15:89750959:C:G	E91D	0.995
15:89750855:A:G	L126P	0.991
15:89750867:T:A	K122M	0.991
15:89750834:A:T	I133N	0.990
15:89750846:G:T	A129D	0.990
15:89750908:A:C	F108L	0.990
15:89750908:A:T	F108L	0.990
15:89750910:A:G	F108L	0.990
15:89750948:A:G	M95T	0.990
15:89750868:T:C	K122E	0.989
15:89750952:G:T	R94S	0.989
15:89750861:T:A	E124V	0.988
15:89750838:A:C	Y132D	0.987
15:89750838:A:G	Y132H	0.987
15:89750849:A:G	L128P	0.987
15:89750968:A:C	S88R	0.987
15:89750968:A:T	S88R	0.987
15:89750970:T:G	S88R	0.987
15:89750918:A:G	L105P	0.986
15:89750961:C:T	E91K	0.986
15:89750837:T:G	Y132S	0.984
15:89750847:C:G	A129P	0.984

dbSNP variants (sampled 300 via entrez): RS1000226414 (15:89750937 C>A,T), RS1000329520 (15:89733710 A>G), RS1000489282 (15:89736682 C>G), RS1000695799 (15:89732157 G>A), RS1000788795 (15:89732499 A>C), RS1000898542 (15:89742076 C>T), RS1000903175 (15:89737896 C>A), RS1001057463 (15:89743720 A>C), RS1001302682 (15:89742174 G>A,C), RS1001356809 (15:89748914 C>A), RS1001375574 (15:89748060 C>G,T), RS1001476113 (15:89747841 G>A,C,T), RS1001624918 (15:89752576 T>A), RS1001846126 (15:89742435 A>G), RS1002008858 (15:89752199 G>A,C)

Disease associations

OMIM: gene MIM:608689 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Moderate	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Moderate	AD

Mondo (1): congenital heart disease (MONDO:0005453)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010796_4586	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004327	electrocardiography

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Benzo(a)pyrene	decreases methylation, affects methylation, decreases expression	2
Cadmium	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	increases expression	1
bisphenol A	decreases expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	decreases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Vorinostat	decreases expression	1
Leflunomide	decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	decreases expression	1
Diosgenin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Lead	affects expression	1
Methylcholanthrene	affects binding, increases reaction	1
Niclosamide	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE